Finoriq research workspace
Jade Biosciences, Inc. (JBIO) Institutional Holdings & 13F Ownership
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for. Review JBIO institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
- Company
- Jade Biosciences, Inc. (JBIO)
- Ticker
- JBIO
- Market Cap
- $966M
- Latest Price
- $19.57
- Industry
- Biotech & Pharma
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.